These findings indicate that the anti-obesity and glucose-lowering effects of VS may be due to the inhibition of HFD-induced adipocyte hypertrophy by suppressing adipocyte differentiation, accompanied by enhanced insulin sensitivity. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.